Peptides — ADMETatlas

Skip to content

peptide evidence atlas

Browse

Peptides

Browse peptide identities and open a record for ADMET evidence.

On page: 20
API: live

Total

502

Start from a developability question

Counts show peptides with evidence at that endpoint

ADMETatlas

peptide evidence atlas

ADMETatlas is an open, curated atlas of ADMET evidence for therapeutic peptides — spanning developability, membrane permeability and blood–brain-barrier transport, immune-recognition context, and approved-product context. Every measurement stays linked to its original source, with stable identifiers and transparent curation, so results can be traced, cited, and reproduced.

Browse

Peptides Products Evidence Context signals Descriptors

Resource

Developability Comparator

Context signals

Developability

Profile Comparator

Resources

Manual Explanations Statistics Download License About

Is it orally or systemically bioavailable?

Bioavailability

47 peptides→

Can it cross cell membranes?

Permeability

7,622 peptides→

Does it resist proteolysis in serum or plasma?

Serum/plasma stability

502 peptides→

What is its plasma half-life?

Half-life (PK)

988 peptides→

How is it cleared?

Clearance

Is it selective over host cells?

Hemolysis metric

455 peptides→

Filters1

Search

ADMET property1

Filter by the measured property; interpretation still depends on assay/model context.

Exposure

Distribution

Stability1

Persistence

Safety

Physchem

Developability

Lipinski Rule-of-5 / beyond-Rule-of-5 space, computed in-silico from structure.

#					View
1	Exenatide ATLPC0009237exenatide	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAP… 39 aaCanonical sequence	11 endpoints
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Stack

© 2026 ADMETatlas, an academic peptide ADMET evidence atlas.

143

rows

2D structure of Semaglutide

Semaglutide

ATLPC0011948·semaglutide

H-Aib-EGTFTSDVSSYLEGQAAKEFIAWLVRGRG

—·Modified sequence

9

endpoints

73

rows

2D structure of Liraglutide

Liraglutide

ATLPC0024280·liraglutide

HAEGTFTSDVSSYLEGQAAK(Î³-Glu-palmitoy…

—·Modified sequence

9

endpoints

32

rows

2D structure of Lixisenatide

Lixisenatide

ATLPC0015930·lixisenatide

HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAP…

44 aa·Canonical sequence

9

endpoints

14

rows

2D structure of Glucagon

Glucagon

ATLPC0002714·glucagon+1

HSQGTFTSDYSKYLDSRRAQDFVQWLMNT

29 aa·Canonical sequence

8

endpoints

28

rows

2D structure of Eptifibatide

Eptifibatide

ATLPC0004545·eptifibatide

Mpr-Har-GDWPC

—·Modified sequence

7

endpoints

11

rows

2D structure of Nesiritide

Nesiritide

ATLPC0010885·nesiritide

SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH

32 aa·Canonical sequence

5

endpoints

19

rows

2D structure of Thymalfasin

Thymalfasin

ATLPC0003634·thymalfasin

SDAAVDTSSEITTKDLKEKKEVVEEAEN

28 aa·Canonical sequence

5

endpoints

6

rows

ATLPC0023033

AKRLKKLAKKIWKWK

15 aa·Canonical sequence

4

endpoints

15

rows

ATLPC0008097

HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR

30 aa·Canonical sequence

3

endpoints

91

rows

ATLPC0000870

IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY

34 aa·Canonical sequence

3

endpoints

50

rows

ATLPC0015923

YGGFL

5 aa·Canonical sequence

3

endpoints

47

rows

ATLPC0025117

LRKLRKRLLRLVGRQLEEFL

20 aa·Canonical sequence

3

endpoints

22

rows

ATLPC0012326

FNAPFDVGIKLSGAQYQQHGRAL

23 aa·Canonical sequence

3

endpoints

21

rows

ATLPC0026740

YGGFM

5 aa·Canonical sequence

3

endpoints

24

rows

ATLPC0031703

DRVYIHPFHL

10 aa·Canonical sequence

3

endpoints

13

rows

ATLPC0000518

CKGKGAKCSRLMYDCCTGSCRSGKC

25 aa·Canonical sequence

3

endpoints

13

rows

ATLPC0024443

QHSQITKV

8 aa·Canonical sequence

3

endpoints

8

rows

ATLPC0003166

QHTQITKV

8 aa·Canonical sequence

3

endpoints

8

rows

ATLPC0033580

VDKPPYLPRPRPIRrPGGr

19 aa·Canonical sequence

3

endpoints

8

rows

1–20 / 502

…

Go to